Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (161-170 of 219) with videos related to

Pageof 22
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
Rheumatology (Oxford, England)|September 22, 2021
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trialsMark C Genovese, Eduardo Mysler, Tetsuya Tomita, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Rheumatology (Oxford, England)|May 26, 2020
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trialsMark C Genovese, Eduardo Mysler, Tetsuya Tomita, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2023
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trialEmma Guttman-Yassky, Jonathan I Silverberg, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|January 11, 2003
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasisKim A Papp, Lyn Guenther, Bernard Boyden, et al.
The British Journal of Dermatology|March 21, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Diamant Thaçi, Kim A Papp, et al.
Rheumatology and Therapy|April 29, 2021
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 StudyPhilip J Mease, Apinya Lertratanakul, Kim A Papp, et al.
The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.
Drug Safety|June 2, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLARRobert Bissonnette, Alice B Gottlieb, Richard G Langley, et al.
Pageof 22

Showing results (161-170 of 219) with videos related to

Sort By:
Pageof 22
Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.
Rheumatology (Oxford, England)|September 22, 2021
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trialsMark C Genovese, Eduardo Mysler, Tetsuya Tomita, et al.
JAMA Dermatology|July 9, 2025
Ixekizumab and Malignant Neoplasms: A Pooled Analysis of Data From 25 Randomized Clinical TrialsJoseph F Merola, Kim A Papp, Atul Deodhar, et al.
Rheumatology (Oxford, England)|May 26, 2020
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trialsMark C Genovese, Eduardo Mysler, Tetsuya Tomita, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 1, 2023
Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trialEmma Guttman-Yassky, Jonathan I Silverberg, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|January 11, 2003
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasisKim A Papp, Lyn Guenther, Bernard Boyden, et al.
The British Journal of Dermatology|March 21, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trialsAndrew Blauvelt, Diamant Thaçi, Kim A Papp, et al.
Rheumatology and Therapy|April 29, 2021
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 StudyPhilip J Mease, Apinya Lertratanakul, Kim A Papp, et al.
The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.
Drug Safety|June 2, 2021
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLARRobert Bissonnette, Alice B Gottlieb, Richard G Langley, et al.
Pageof 22